BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36469217)

  • 1. New insight into immune checkpoint inhibitors in the treatment of advanced renal cell carcinoma.
    Wang H; Zhu Z; Zhang Y; Jiang T; Zhang M; Wang Z; Zhang Y; Zhao A; Su B
    Sci China Life Sci; 2023 Apr; 66(4):875-878. PubMed ID: 36469217
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
    Sarkis J; Khalil N; Alkassis M
    Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
    [No Abstract]   [Full Text] [Related]  

  • 3. What advances have been made in immune-therapy for renal cell carcinoma?
    Verzoni E; Grassi P; Ratta R
    Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma.
    Song Y; Peng Y; Qin C
    World J Urol; 2023 Aug; 41(8):2301-2302. PubMed ID: 37410104
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions.
    Rambhia A; Patel RD; Okhawere KE; Korn TG; Badani KK
    Urol Oncol; 2021 Oct; 39(10):664-677. PubMed ID: 34312081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor combination therapy leads to more nephrotoxicity in advanced renal cell carcinoma patients.
    Song Y; Han S; Xu T
    World J Urol; 2023 Jul; 41(7):1991-1992. PubMed ID: 37286737
    [No Abstract]   [Full Text] [Related]  

  • 7. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
    Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
    Gulati S; Vaishampayan U
    Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
    Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
    Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?
    Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N
    Future Oncol; 2022 Feb; 18(5):519-522. PubMed ID: 35067079
    [No Abstract]   [Full Text] [Related]  

  • 11. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
    Nada A; Bhat R; Cousins J
    Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
    Saliby RM; Labaki C; Jammihal TR; Xie W; Sun M; Shah V; Saad E; Kane MH; Kashima S; Sadak K; El Zarif T; Poduval D; Motzer RJ; Powles T; Rini BI; Albiges L; Pal SK; McGregor BA; McKay RR; Signoretti S; Van Allen EM; Shukla SA; Choueiri TK; Braun DA
    Cancer Cell; 2024 May; 42(5):732-735. PubMed ID: 38579722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
    Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
    Front Immunol; 2021; 12():653358. PubMed ID: 33746989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapeutic approaches in renal cell carcinoma.
    Parekh H; Rini BI
    Expert Rev Anticancer Ther; 2015; 15(11):1305-14. PubMed ID: 26376584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade in renal cell carcinoma.
    Rappold PM; Silagy AW; Kotecha RR; Hakimi AA
    J Surg Oncol; 2021 Mar; 123(3):739-750. PubMed ID: 33595892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials.
    Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
    Clin Immunol; 2021 Nov; 232():108876. PubMed ID: 34740840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
    de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
    Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.